To Compare the Reactogenicity and Immunogenicity of Recommended COVID-19 Vaccines in Young Adolescents in Hong Kong
Latest Information Update: 22 Jul 2022
At a glance
- Drugs AZD 1222 (Primary) ; SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms COVAC
- 10 Nov 2021 Planned number of patients changed from 900 to 1000.
- 07 Apr 2021 Status changed from not yet recruiting to recruiting.
- 22 Mar 2021 New trial record